OBJECTIVE: To examine the costs of routine outpatient follow-up after curative treatment of @entity1204 , and to determine whether this leads to early detection of recurrence or survival. The impact of specific disease characteristics on survival is examined. DESIGN: Retrospective chart review, and calculation of costs. SETTING: Ottawa @entity5 Centre-Civic Division (ORCC-C). @entity1 : All 432 @entity1 referred to the ORCC-C with @entity1204 between 1982 and 1991 who received treatment with curative intent and who continued with routine follow-up. RESULTS: @entity5 recurred in 50 @entity1 (11.57%). There was no statistically significant difference in overall survival between @entity1 with symptomatic and asymptomatic recurrences, or between those with recurrences detected during routine follow-up visits or in the interval between routine visits. Of 4830 Papanicolaou (Pap) smears performed routinely, @entity5 was detected in 6 cases. The mean cost of the routine follow-up procedures for each @entity1 with a recurrence was  19,200. CONCLUSION: Intensive follow-up of @entity1 with @entity1204 does not result in improved survival. A prospective randomized study is warranted to evaluate other potential benefits of follow-up, such as improved quality of life or decreased morbidity. There is no economic or clinical justification for the routine use of the Pap smear in the follow-up of @entity1 with @entity1204 . The potential benefits of routine follow-up in @entity5 with favourable prognoses warrant critical evaluation.

Costs and benefits of routine follow-up after curative treatment for XXXX .

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Regional Cancer', 'endometrial cancer and other types of cancer', 'cancer', 'Cancer']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
